Introduction
Uterine fibroids and adenomyosis are very common gynaecological disorders that affect women during their reproductive age and compromise their quality of life. The two conditions are frequently the underlying causes of dysmenorrhea, menorrhagia, urinary symptoms, and subfertility. High-intensity focused ultrasound (HIFU) is a newly developed non-invasive surgery that uses an external ultrasound energy source to induce thermal ablation of tissue deep under the intact skin by concentrating the energy of ultrasound waves. 1 It not only offers organ preservation of uterus, but also minimises harm to patients compared with other treatments such as hysterectomy and myomectomy. 1, 2 The underlying causes of these two hormonal-dependent benign conditions are not well defined, although studies have shown that persistence of a high-pressure living environment may cause hormone disorders that may lead to the development of benign uterine diseases. 3 It has become more appreciated that the underlying cause of the manifestation of a disease at a given organ is due to discordance among physical, psychological and social behaviour. Evaluation of the lifestyles of adenomyosis and uterine fibroid patients revealed a connection between unhealthy lifestyles (lack of exercise, unbalanced diet, poor sleeping quality and poor management of stress and emotion) and the development of uterine fibroids and adenomyosis. Although the effect of exercise on improving the emotional state of women has been reported, 4 its impact on the therapeutic efficacy of any given treatment (certainly not HIFU treatment) has not been vigorously examined.
Here, we report the first preliminary observation on the enhancing effect of exercise post-HIFU treatment efficacy in uterine fibroids and adenomyosis.
Methods

Patients
This retrospective study included uterine fibroid or adenomyosis patients who received ultrasound-guided highintensity focused ultrasound (HIFU) at Chongqing Haifu Hospital between January 2011 and August 2015. A total of 83 fibroid patients and 102 adenomyosis patients were included in this study.
The inclusion criteria for the 83 patients were: (1) age 25-35 years, wish to become pregnant; (2) single intermural-type uterine fibroid; (3) uterine fibroid 3-6 cm; (4) diagnosis of uterine fibroid confirmed by enhanced MRI; (5) attended 1-year follow up with enhanced MRI. The patients were divided into two groups: a 'No exercise group' of patients who were treated between 2011 and 2013, during which time the exercise intervention regimen was neither introduced and reinforced, and an 'Exercise group' of patients who were treated between 2014 and 2015, during which time the exercise intervention regimen was introduced and follow ups on exercise were conducted.
The inclusion criteria for the adenomyosis patients were: (1) age >8 years, wish to become pregnant; (2) diagnosis of adenomyosis confirmed by enhanced MRI; (3) attended 6-month follow up with enhanced MRI. The patients were divided into two groups: a 'No exercise group' of patients who were treated between 2011 and 2013, during which time the exercise intervention regimen was neither introduced nor reinforced, and an 'Exercise group' of patients who were treated between 2014 and 2015, during which time the exercise intervention regimen was introduced and follow ups on exercise were conducted; (4) high VAS scores >7.
HIFU ablation
In all patients, careful bowel and skin preparations were carried out before the HIFU procedure. 5 Briefly, bowel preparation involved a liquid food diet for about 3 days. In the skin preparation, the hair of the anterior abdomen was shaved from the umbilicus to the superior border of the symphysis pubis, followed by a de-greasing process using 70% ethanol. At 30 minutes prior to treatment the skin was de-gassed using a vacuum device. Finally, for bowel safety, a degassed water balloon was placed on the abdominal wall to push the bowel out of the acoustic pathway. This balloon lay between the transducer in the machine and the abdominal wall.
All patients were successfully treated with HIFU. In this study, HIFU treatment was performed using an USgHIFU system (JC200, Haifu Medical Technology Co., Chongqing, China). Patients were positioned in a prone position on the treatment bed, with the abdominal wall immersed in de-gassed water. Conscious sedation was administered during the procedure to control the patients' reactions and prevent unnecessary body movement. Fentanyl (maximum 200 lg), and dormicum (maximum 2 mg) were used for sedation. Paracetamol (10 mg/ml) was used for pain relief. During treatment, patients were requested to lie still and to report any discomfort, including burning of the skin or lower abdominal, leg, sciatic or buttock pain. USgHIFU ablation treatment was terminated when there was an obvious general or great grey-scale change inside the fibroid lesion.
Evaluation of clinical symptoms after treatment
All patients were required to undergo a pelvic contrastenhanced MR imaging examination pretreatment and at the 1-year follow up for fibroids and the 6-month follow up for adenomyosis. The size, volume and T2 signal intensity and the presence of enhancement (blood supply) after gadolinium injection were recorded in the pretreatment MR imaging. Non-perfused volume (NPV) was measured with contrast-enhanced post-treatment MR images to estimate fibroid necrosis volume. The ablation rate, defined as NPV/fibroid volume 9 100%, was also recorded.
The absorption rate baseline for uterine fibroid is about 50.13%. 6 At the 1-year follow up with MRI, if the uterine fibroid absorption rate was higher than at baseline, the patient was judged to have a satisfactory absorption rate.
The degree of dysmenorrhea was scored before and after HIFU treatment and compared with change in quality of life. The Visual Analogue Scale (VAS) scoring system is as follows: (1) score 1-3 for mild pain, (2) score 4-6 for moderate pain and (3) score >7 for severe pain). Symptom relief and improved quality of life were indirectly measured by reduction of the VAS score post-HIFU treatment. A 6-month follow up was conducted with MRI.
Statistical analysis
Statistical analysis was conducted using IBM SPSS Statistics 19 software. The results were expressed as mean AE variance (minimum-maximum) and mean AE SD (SE). Uterine volume, and adenomysis score before and after treated HIFU were all compared with baseline with a paired t-test. P < 0.05 was defined as statistically significant.
Results
Baseline characteristics of patients
As shown in Table 1 , 83 patients with single uterine fibroid underwent HIFU and were followed up for 1 year. The mean age was 30.17 AE 10.37 years (21.00-35.00) in the 'no exercise group' and 31.84 AE 26.00 years (26.00-35.00) in the 'exercise group'. The mean uterine fibroid volume before treatment was 99 599.50 AE 60 779.58 mm 3 (median = 19 220.19) in the 'no exercise group' and 143 710.60 AE 35055.48 mm 3 (median = 11 085.52) in the 'exercise group'. A comparison of baseline data in the two groups is shown in Table 1 ; there were no significant differences in age, height, BMI, sonication time or therapeutic dose between the two groups (P > 0.05).
As shown in Table 2 , 102 patients with adenomyosis underwent HIFU and were followed up for 6 months. Table 2 ; there were no significant differences in age, height, BMI, sonication time or therapeutic doses between the two groups (P > 0.05).
Evaluation of treatment effectiveness
MRI imaging analysis was performed before and after HIFU treatment and at the indicated follow up times for all patients in this study. Most of the T2 signal intensities of uterine fibroids (43/51 patients, 84.3%, Table 3 ) and adenomyosis were low (20/32 patients, 62.5%, Table 4 ). There were no significant baseline differences in T2 MRI signal between the uterine fibroid and adenomyosis groups. In this study, all patients received HIFU treatment from a single experienced HIFU doctor at the Chongqing Haifu Hospital, which helped to eliminate inter-personal differences in applying HIFU treatment. The severity of dysmenorrhea before and 6 months after the HIFU treatment was assessed using VAS.
Exercise post-HIFU treatment reduces recurrence rate and enhances uterine fibroid absorption
We analysed the effect of post-HIFU treatment exercise on uterine fibroid absorption. Of the 83 uterine fibroid patients who attended the 1-year follow up, the recurrence rate for the 'no exercise group' was 7.8% (4/51 patients) and 27.7% patients had satisfactory fibroid absorption (13/ 51). In comparison, the recurrence rate for the 'exercise group' was null (0/32) and 68.8% patients had satisfactory fibroid absorption (22/32). Based on published work, the satisfactory uterine fibroid absorption at 1-year post-HIFU treatment was approximately 50%. 6 Among the 51 patients in the 'no exercise' group, 44 wished to become pregnant. At the 1-year follow up, three were pregnant (6.9%, 3/44). Of the 13 patients who achieved satisfactory fibroid absorption (i.e. over 50%), 12 wished to become pregnant. The three pregnancy events all occurred in women who had achieved satisfactory fibroid absorption (3/13, 25%).
Among the 32 patients in the 'exercise group', 25 wished to become pregnant. At the 1-year follow up, four had become pregnant (4/25, 16%). Further examination of the four pregnant patients revealed that they had the following in common: (1) satisfactory absorption, (2) no recurrence, (3) a habit of exercise. It appears that satisfactory fibroid absorption may be necessary for a successful pregnancy after HIFU and that exercise can further improve the chances of pregnancy (Figure 1) .
We compared changes in uterine volume in the two groups before and at the 1-year follow up. 3 , median 2733.84) at 1-year post-HIFU treatment, the reduction was more pronounced in the 'exercise group'. With the addition of the exercise regimen, post-HIFU treatment, the efficacy of HIFU in reducing the uterine volume was augmented (Table 1, Figure 2ii , P = 0.032).
Based on the above observations, we conclude that exercise post-HIFU treatment significantly enhanced uterine fibroid absorption.
Exercise post-HIFU treatment can significantly enhance the improvement of symptom relief for adenomyosis
We analysed the effect of post-HIFU treatment exercise on pain symptom relief. Among the 102 adenomyosis patients who attended the 6-month follow up, 33.3% patients in the 'no exercise group' achieved a reduction of VAS pain score of more than 1 (15/45). In comparison, for the 57 patients in the 'exercise group', 68.4% patients achieved a reduction of VAS pain score more than 1 (39/57), 35 of whom patients self-reported have taken up exercise (89.7%).
We compared changes in uterine volume in the two groups before and at the 6-month follow up. Although the uterine volume of the 'exercise group' (412 931.64 AE 520 233.53 mm 3 , median 77 551.84) appeared to be larger than that of the 'no exercise group' (304 778.11 AE 139 793.87 mm 3 , median 20 839.24), the difference was not statistically significant (Table 2, Figure 2i , P = 0.20). Although the uterine volume was reduced in both the 'no exercise group' (302 672.36 AE 167 366.18 mm 3 , median 24 949.48) and the 'exercise group' (269 374.61 AE 153 022.97 mm 3 , median 27 483.74) 6 months post-HIFU treatment, there was no statistically significant difference in the changes of the uterine volume between the two study groups (Table 2, Figure 2ii , P = 0.23).
In contrast to the observations concerning uterine volume, exercise significantly enhanced symptom relief. The VAS scores before HIFU treatment were 8.61 AE 1.07 for the 'no exercise group' and 8.37 AE 0.87 for the 'exercise group'; there was no baseline difference in VAS pain score between the two groups ( Figure 3i , P = 0.26). HIFU treatment alone reduced the VAS score to 6.03 AE 2.97 for the 'no exercise group'. With the addition of the exercise regimen post-HIFU treatment, the efficacy of HIFU in reducing VAS was augmented. The VAS score for the 'exercise group' was reduced to 4.07 AE 2.66, from severe to moderate. The difference in the VAS score was significant between the two study groups (Figure 3ii , P = 0.002).
Based on the above observations, we conclude that exercise post-HIFU treatment significantly enhanced the reduction of VAS pain score and thus symptom relief.
Discussion
The high incidence of uterine fibroids and adenomyosis poses a worldwide health risk for women of child-bearing age, affecting the quality of their lives and even in some cases causing sterility. Hysterectomy is currently the only medical treatment that can cure uterine fibroids and adenomysis. 7 However, hysterectomy, due to loss of the uterus, leads to the loss of fertility, endocrine disorders and psychological disturbances. 8 The newly developed HIFU treatment not only preserves the uterus but also offers a safe and effective treatment of uterine fibroids and adenomyosis. 5 However, factors that influence recurrence, longterm treatment efficacy and pregnancy after HIFU have not been studied.
It has become more appreciated that the underlying cause of the manifestation of a disease at a given organ is a discordance among physical, psychological and social behaviour. Evaluation of the lifestyles of adenomyosis and uterine fibroid patients revealed a connection between unhealthy lifestyles (lack of exercise, unbalanced diet, poor sleeping quality and poor management of stress and emotion) and the development of uterine fibroids and adenomyosis. Although the effect of exercise on improving the emotional state of women has been reported, 4 its impact on the therapeutic efficacy of any given treatment (certainly not HIFU treatment) has not been vigorously examined.
Here, we reported the first preliminary observation on the enhancing effect of exercise on post-HIFU treatment efficacy in uterine fibroids and adenomyosis. Exercise can help relieve the symptoms of dysmenorrhea and also improve the uterine fibroid absorption after 1 year.
There are several deficiencies in the study design due to the retrospective nature of this study. First, the patient cohorts of the two study groups ('no exercise group' versus 'exercise group') were from different periods of time, although they were treated at the same hospital, with the same machine and by the same doctor; future studies will compare patients from the same periods of time. Secondly, the presence or absence of exercise was measured using a self-reporting system at the time of the follow up. The types of exercise, the intensity and the frequency of exercise were not specified. Thus, the measure of the effect of exercise is qualitative. Although we observed a statistically significant effect of exercise on enhancing the therapeutic efficacy in fibroids and adenomyosis patients, the effect would be more accurately quantified if the type of exercise and the intensity were specified. Finally, the size of patient cohorts is relatively small. Although we were able to detect an enhancing effect of exercise on the efficacy of HIFU, larger cohorts are needed to confirm these results.
Future perspective and randomised RCT studies are required to provide more convincing evidence for adding exercise to the post-treatment management of uterine fibroids and adenomyosis.
Conclusion
Based on the clinical observations and analyses we have presented, we conclude that developing a habit of regular exercise post-HIFU treatment may reduce the recurrence of uterine fibroids, enhance uterine fibroid absorption, and increase the chance of pregnancy. Exercise in addition to HIFU is more effective at reducing the VAS score and thus the symptom relief. Therefore, exercise should be recommended to patients as part of the post-treatment disease management plan.
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